Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way.

Eliyatkın N, Yalçın E, Zengel B, Aktaş S, Vardar E.

J Breast Health (2013). 2015 Apr 1;11(2):59-66. doi: 10.5152/tjbh.2015.1669. eCollection 2015 Apr. Review.

2.

Molecular Classification of Lobular Carcinoma of the Breast.

Fu D, Zuo Q, Huang Q, Su L, Ring HZ, Ring BZ.

Sci Rep. 2017 Mar 17;7:43265. doi: 10.1038/srep43265.

3.

Similar outcomes between adenoid cystic carcinoma of the breast and invasive ductal carcinoma: a population-based study from the SEER 18 database.

Chen QX, Li JJ, Wang XX, Lin PY, Zhang J, Song CG, Shao ZM.

Oncotarget. 2017 Jan 24;8(4):6206-6215. doi: 10.18632/oncotarget.14052.

4.

Triple-negative breast cancer: is there a treatment on the horizon?

Yao H, He G, Yan S, Chen C, Song L, Rosol TJ, Deng X.

Oncotarget. 2017 Jan 3;8(1):1913-1924. doi: 10.18632/oncotarget.12284. Review.

5.

Improving Pathological Assessment of Breast Cancer by Employing Array-Based Transcriptome Analysis.

Mihály Z, Győrffy B.

Microarrays (Basel). 2013 Aug 29;2(3):228-42. doi: 10.3390/microarrays2030228. Review.

6.

Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.

Fusco N, Geyer FC, De Filippo MR, Martelotto LG, Ng CK, Piscuoglio S, Guerini-Rocco E, Schultheis AM, Fuhrmann L, Wang L, Jungbluth AA, Burke KA, Lim RS, Vincent-Salomon A, Bamba M, Moritani S, Badve SS, Ichihara S, Ellis IO, Reis-Filho JS, Weigelt B.

Mod Pathol. 2016 Nov;29(11):1292-1305. doi: 10.1038/modpathol.2016.134. Epub 2016 Aug 5.

7.

Decoding Intratumoral Heterogeneity of Breast Cancer by Multiparametric In Vivo Imaging: A Translational Study.

Schmitz J, Schwab J, Schwenck J, Chen Q, Quintanilla-Martinez L, Hahn M, Wietek B, Schwenzer N, Staebler A, Kohlhofer U, Aina OH, Hubbard NE, Reischl G, Borowsky AD, Brucker S, Nikolaou K, la Fougère C, Cardiff RD, Pichler BJ, Schmid AM.

Cancer Res. 2016 Sep 15;76(18):5512-22. doi: 10.1158/0008-5472.CAN-15-0642. Epub 2016 Jul 27.

PMID:
27466286
8.

Breed- and age-related differences in canine mammary tumors.

Kim HW, Lim HY, Shin JI, Seung BJ, Ju JH, Sur JH.

Can J Vet Res. 2016 Apr;80(2):146-55.

9.

Prognosis of subtypes of the mucinous breast carcinoma in Chinese women: a population-based study of 32-year experience (1983-2014).

Pan B, Yao R, Shi J, Xu QQ, Zhou YD, Mao F, Lin Y, Guan JH, Wang XJ, Zhang YN, Zhang XH, Shen SJ, Zhong Y, Xu YL, Zhu QL, Liang ZY, Sun Q.

Oncotarget. 2016 Jun 21;7(25):38864-38875. doi: 10.18632/oncotarget.8778.

10.

Assessment of Tumor Heterogeneity, as Evidenced by Gene Expression Profiles, Pathway Activation, and Gene Copy Number, in Patients with Multifocal Invasive Lobular Breast Tumors.

Norton N, Advani PP, Serie DJ, Geiger XJ, Necela BM, Axenfeld BC, Kachergus JM, Feathers RW, Carr JM, Crook JE, Moreno-Aspitia A, Anastasiadis PZ, Perez EA, Thompson EA.

PLoS One. 2016 Apr 14;11(4):e0153411. doi: 10.1371/journal.pone.0153411. eCollection 2016.

12.

Biomarkers in triple negative breast cancer: A review.

Yadav BS, Chanana P, Jhamb S.

World J Clin Oncol. 2015 Dec 10;6(6):252-63. doi: 10.5306/wjco.v6.i6.252. Review.

13.

Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives.

Inno A, Bogina G, Turazza M, Bortesi L, Duranti S, Massocco A, Zamboni G, Carbognin G, Alongi F, Salgarello M, Gori S.

Oncologist. 2016 Jan;21(1):28-32. doi: 10.1634/theoncologist.2015-0309. Epub 2015 Dec 9. Review.

14.

Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.

Cossu-Rocca P, Orrù S, Muroni MR, Sanges F, Sotgiu G, Ena S, Pira G, Murgia L, Manca A, Uras MG, Sarobba MG, Urru S, De Miglio MR.

PLoS One. 2015 Nov 5;10(11):e0141763. doi: 10.1371/journal.pone.0141763. eCollection 2015.

15.

Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies.

Nounou MI, ElAmrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H.

Breast Cancer (Auckl). 2015 Sep 27;9(Suppl 2):17-34. doi: 10.4137/BCBCR.S29420. eCollection 2015. Review.

16.

Lack of CD151/integrin α3β1 complex is predictive of poor outcome in node-negative lobular breast carcinoma: opposing roles of CD151 in invasive lobular and ductal breast cancers.

Romanska HM, Potemski P, Krakowska M, Mieszkowska M, Chaudhri S, Kordek R, Kubiak R, Speirs V, Hanby AM, Sadej R, Berditchevski F.

Br J Cancer. 2015 Nov 3;113(9):1350-7. doi: 10.1038/bjc.2015.344. Epub 2015 Sep 29.

17.

Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.

Munzone E, Giobbie-Hurder A, Gusterson BA, Mallon E, Viale G, Thürlimann B, Ejlertsen B, MacGrogan G, Bibeau F, Lelkaitis G, Price KN, Gelber RD, Coates AS, Goldhirsch A, Colleoni M; International Breast Cancer Study Group and the BIG 1-98 Collaborative Group..

Ann Oncol. 2015 Dec;26(12):2442-9. doi: 10.1093/annonc/mdv391. Epub 2015 Sep 19.

19.

Genomic landscape of adenoid cystic carcinoma of the breast.

Martelotto LG, De Filippo MR, Ng CK, Natrajan R, Fuhrmann L, Cyrta J, Piscuoglio S, Wen HC, Lim RS, Shen R, Schultheis AM, Wen YH, Edelweiss M, Mariani O, Stenman G, Chan TA, Colombo PE, Norton L, Vincent-Salomon A, Reis-Filho JS, Weigelt B.

J Pathol. 2015 Oct;237(2):179-89. doi: 10.1002/path.4573. Epub 2015 Jul 14.

20.

The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.

Guerini-Rocco E, Hodi Z, Piscuoglio S, Ng CK, Rakha EA, Schultheis AM, Marchiò C, da Cruz Paula A, De Filippo MR, Martelotto LG, De Mattos-Arruda L, Edelweiss M, Jungbluth AA, Fusco N, Norton L, Weigelt B, Ellis IO, Reis-Filho JS.

J Pathol. 2015 Oct;237(2):166-78. doi: 10.1002/path.4566. Epub 2015 Jul 29.

Supplemental Content

Support Center